Standort in Deutschland, wo man günstige und qualitativ hochwertige Kamagra Ohne Rezept Lieferung in jedem Teil der Welt zu kaufen.

Wenn das Problem der Verringerung der Potenz berührt mich persönlich war ich schockiert, dass das passiert gerade mit mir levitra Übrigens jeder leisten und gibt eine sofortige Wirkung ohne Hausarbeiten Anwendungen.

Microsoft word - referenciasbibliograficas_sm_suplemento.doc

Rev Cubana Aliment Nutr 2012;22(1 Supl 2):S54-S64

REFERENCIAS BIBLIOGRÁFICAS

1. Rodríguez Porto AL, Sánchez León M, Martínez LL. Síndrome metabólico- Enfoque actual.
2. Martínez de Morentín BE, Rodríguez MC, Martínez JA. Síndrome metabólico, resistencia a la insulina y metabolismo tisular. Endocrinol Nutr 2003;50:324-33. 3. López ME, Sosa MA, Paulo N. Síndrome metabólico. Revista de Posgrado de la VIa Cátedra 4. Eckel RH, Grandy SM, Zimmet PZ. The Metabolic syndrome. Lancet 2005;365:1415-26. 5. Barrera MP, Pinilla AE, Cortéz E. Síndrome metabólico, una mirada interdisciplinaria. Rev 6. Cho LW. Metabolic syndrome. Singapore Med J 2011;52:779-85. 7. Hadiyannakis S. The Metabolic syndrome in children and adolescents. Pediatr Child Health 8. Damiani D, Kuba VM, Cominato L, Damiani D, Dichtchekenian V, Menezes Filho HC. Metabolic syndrome in children and adolescents: doubts about terminology but not about cardiometabolic risks. Arq Bras Endocrinol Metabol 2011;55:576-82. 9. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout and uric calculus disease. Am J Clin Nutr 1956;4:20-34. 10. Avogaro P, Crepaldi G, Enzi G, Tiengo A. Metabolic aspects of essential obesity. 11. Haller H. Epidermiology and associated risk factors of hyperlipoproteinemia. Z Gesamte Inn 12. Phillips GB. Relationship between serum sex hormones and glucose, insulin and lipid abnormalities in men with myocardial infarction. Proc Natl Acad Sci USA 1977;74:1729-33. 13. Phillips GB. Sex hormones, risk factors and cardiovascular disease. Am J Med 1978;65:7-11. 14. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 15. Lara A, Rosas M, Pastelín G, Aguilar C, Attié F, Velásquez MO. Hipercolesterolemia e hipertensión arterial en México: Consolidación urbana actual con obesidad, diabetes y tabaquismo. Arch Cardiol Mex 2004;74: 231-45. 16. ATP III. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high cholesterol. JAMA 2001;285:2486-2497. 17. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome- a new worldwide definition. Lancet. 2005 Sep 24-30;366(9491):1059-62. 18. Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, Arslanian S, Wong G, Bennett P, Shaw J, Caprio S; for the IDF Consensus Group. The metabolic syndrome in children and adolescents- an IDF consensus report. Pediatr Diabetes 2007;8:299-306. 19. Zimmet P, Alberti G, Kaufman F, Tajima N, Silink M, Arslanian S, Wong G, Bennett P, Shaw J, Caprio S; for the International Diabetes Federation Task Force on Epidemiology and Prevention of Diabetes. The metabolic syndrome in children and adolescents. Lancet 2007;369(9579):2059-61. 20. Ford ES, Li C. Defining the Metabolic syndrome in children and adolescents: Will the real definition please stand up? J Pediatr 2008;152:160-4. 21. Camarillo Romero E, Domínguez García MV, Amaya Chávez A, Huitrón Bravo G, Majluf Cruz A. Dificultades en la clasificación del síndrome metabólico: El ejemplo de los adolescentes en México. Salud Pública Méx [serial on the Internet] 2010;52:0-0 [Citada: 15 de Agosto del 2011]. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-36342010000600007&lng=es. 22. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW et al. Obesity and the Metabolic Syndrome in Children and Adolescents. N Engl J Med 2004;350:2362-2374. 23. Rosas Guzmán J, Torres Tamayo M, Calzada León R, Sinay I, Costa Gil J, de Loredo L et al. Guía ALAD: Diagnóstico, control, prevención y tratamiento del Síndrome Metabólico en Pediatría. Rev Asoc Latin Diab 2009;17:16-31. 24. Olaiz Fernández G, Rivera Dommarco J, Shamah-Levy T, Rojas R, Villalpando Hernández S, Hernández Avila M et al. Encuesta Nacional de Salud y Nutrición. INSAP Instituto Nacional de Salud Pública. Cuernavaca: 2006. 25. Isordia Salas I, Santiago Germán D, Rodríguez Navarro H, Almaráz Delgado M, Leaños Miranda A, Anaya Gómez F, Borrayo Sánchez G, Majluf Cruz A. Prevalence of Metabolic Syndrome components in an urban mexican sample: Comparison between two classifications. Exp Diabetes Res 2012;2012:202540. 26. García García E, De la Llata Romero M, Kaufer-Horwitz M, Tusié Luna MT, Calzada León R, Vázquez Velázquez V et al. La obesidad y el síndrome metabólico como problema de salud pública: una reflexión. Salud Pública Méx [serial on the Internet] 2008;50:530-47 [Citada: 8 de Agosto del 2011]. Disponible en: http://dx.doi.org/10.1590/S0036- 36342008000600015. También disponible en: http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0036-36342008000600015&lng=en. 27. Córdova Villalobos JA. El Acuerdo Nacional para la Salud Alimentaria como una estrategia contra el sobrepeso y la obesidad. Cir Cir 2010;78:105-7. 28. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9. 29. Rocchini AP. Childhood obesity and a Diabetes epidemic. N Engl J Med 2002; 346:854-5. 30. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM et al. Prevalence of diabetes and impaired fasting glucose in adults in the US population. National Health and Nutrition Examination Survey 1999–2002. Diabetes Care 2006;29:1263-8. 31. Pelletier EM, Smith PJ, Boye KS, Misurski DA, Tunis SL, Minshall ME. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research. Appl Health Econ Health Policy 2008;6:103-12. 32. Nguyen NT, Nguyen XM, Lane J, Wang P. Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999-2006. Obes Surg 2011;21:351-5. 33. Flegal KM, Ogden CL, Carroll MD. Prevalence and trends in overweight in Mexican- american adults and children. Nutr Rev 2004;62(7 Pt 2):S144-8. 34. Weiss R, Dufour S, Taksali SE. Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet 2003;362:951-7. 35. Ginsberg HN, MacCallum PR. The obesity, Metabolic Syndrome, and type 2 Diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the Metabolic Syndrome and Type 2 Diabetes mellitus. J Cardiometab Syndr 2009;4:113-9. 36. Sinha R, Fisch G, Teague B, Tamborlane WV, Banyas B, Allen K et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl Med 2002;346:802-10. 37. Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 Diabetes in 38. Strauss RS, Pollack HA. Epidemic increase in childhood overweight, 1986-1998. JAMA 39. Wiegand S, Maikowski U, Blankenstein O, Biebermann H, Tarnow P, Gruters A. Type 2 diabetes and impaired glucose tolerance in European children and adolescents with obesity- a problem that is no longer restricted to minority groups. Eur J Endocrinol 2004;151;199-206. 40. Daniels SR, Overweight in children and adolescents. Circulation 2005;111:1999-2012. 41. Márquez Sandoval F, Macedo Ojeda G, Viramontes Hörner D, Fernández Ballart JD, Salas Salvadó J, Vizmanos B. The prevalence of metabolic syndrome in Latin America: a systematic review. Public Health Nutr 2011;14:1702-13. 42. Cárdenas Villarreal VM, López Alvarenga JC, Bastarrachea RA, Rizo Baeza MM, Cortés Castell E. Prevalencia del síndrome metabólico y sus components en adolescentes de la Ciudad de Monterrey, Nuevo León. Arch Cardiol Mex 2010;80:19-26. 43. Rodríguez Morán M., Salazar Vázques B, Violante R. Metabolic Syndrome among children and adolescents aged 10-18 years. Diabetes Care 2004;27:2516-7. 44. Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Prevalence of the Metabolic Syndrome among US adolescents using the definition from the International Diabetes Federation. Diabetes Care 2008;31:587-9. 45. Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the “Metabolic Syndrome” and incidence of type 2 Diabetes. Diabetes 2002;51:3120-7. 46. Gunstad J, Paul RH, Spitznagel MB, Cohen RA, Williams LM, Ronald A et al. Exposure to early life trauma is associated with adult obesity Psychiatr Res 2006;142:31-7. 47. Salihu HM, Weldeselasse HE, Rao K, Marty PJ, Whiteman VE. The impact of obesity on maternal morbidity and feto-infant outcomes among macrosomic infants. J Matern Fetal Neonatal Med 2011;24:1088-94. 48. Raal FJ. Pathogenesis and management of the dyslipidemia of the metabolic syndrome. 49. Luengo Fernández E, Ordóñez Rubio B, Bergua Martínez C, Laclaustra Gimeno M. Obesidad, dislipidemia, y síndrome metabólico. Rev Esp Cardiología 2005;5(Supl):21D-29D. 50. Ghosh S. Macrophage cholesterol homeostasis and metabolic diseases: critical role of cholesteryl ester mobilization. Expert Rev Cardiovasc Ther 2011;9:329-40. 51. Vanderburgh PM. Fat distribution: its physiological significance, health implications, and its adaptation to exercise training. Mil Med 1992;157:189-92. 52. Gil A, Olza J, Gil-Campos M, Gomez-Llorente C, Aguilera CM. Is adipose tissue metabolically different at different sites? Int J Pediatr Obes 2011;6(Suppl 1):13-20. 53. Santana Porbén S. Las adipocitoquinas en la génesis y evolución del Síndrome metabólico. RCAN Rev Cubana Aliment Nutr 2010;20:304-17. 54. Canoy D. Coronary heart disease and body fat distribution. Curr Atheroscler Rep 2010; 55. Sudano I, Roas S, Noll G. Vascular abnormalities in essential hypertension. Curr Pharm Des 56. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A.Endothelial dysfunction in hypertension. J Cardiovasc Pharmacol 2001;38(Suppl 2):S11-S14. 57. Yudkin JS. Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J 58. Dandona P, Aljada A, Chaudburi A, Mohanty P, Garg R. Metabolic Syndrome. A comprehensive perspective based on interactions between obesity, diabetes and inflammation. Circulation 2005; 111:1448-54. 59. Eckel RH, Krauss RM. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 1998;97:2099-100. 60. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998;338:1650-6. 61. Ferrannini E, Muscelli E, Stern MP, Haffner SM. Differential impact of insulin and obesity on cardiovascular risk factors in non-diabetic subjects. Int J Obes Relat Metab Disord 1996;20:7-14. 62. Bacha F, Lee S, Gungor N, Arslanian SA. From pre-diabetes to type 2 diabetes in obese youth: pathophysiological characteristics along the spectrum of glucose dysregulation. Diabetes Care 2010;33:2225-31. 63. van Vliet M, von Rosenstiel IA, Schindhelm RK, Brandjes DP, Beijnen JH, Diamant M. Identifying the metabolic syndrome in obese children and adolescents: do age and definition matter? Curr Clin Pharmacol 2009;4:233-8. 64. Invitti C, Gilardini L, Pontiggia B, Morabito F, Mazzilli G, Viberti G. Period prevalence of abnormal glucose tolerance and cardiovascular risk factors among obese children attending an obesity centre in Italy. Nutr Metab Cardiovasc Dis 2006;16:256-62. 65. Gallardo T V, Avila A A, Unuane M N, Codner E. Fasting glucose versus oral glucose tolerance test for detection of glucose intolerance in obese children. Rev Med Chil 2006; 134:1146-52. 66. Rosenbloom AL. Type 2 Diabetes in children and adolescents. Diabetes Care 2000;3:381-9. 67. Porte D Jr. Mechanisms for hyperglycemia in the metabolic syndrome. The key role of beta- cell dysfunction. Ann NY Acad Sci 1999;892:73-83. 68. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-94. 69. Saini V. Molecular mechanisms of insulin resistance in type 2 diabetes mellitus. World J 70. Schinner S, Scherbaum WA, Bornstein SR, Barthel A. Molecular mechanisms of insulin 71. Rojek A, Niedziela M. Insulin receptor defect as a cause of Rabson-Mendenhall syndrome and other rare genetic insulin resistance syndromes. Pediatr Endocrinol Diabetes Metab 2010;16:205-12. 72. Cena H, Fonte ML, Turconi G. Relationship between smoking and metabolic syndrome. Nutr 73. Masuyama H, Hiramatsu Y. Potential role of estradiol and progesterone in insulin resistance through constitutive androstane receptor. J Mol Endocrinol 2011;47:229-39. 74. Pereira S, Pereira D. Metabolic syndrome and physical activity. Acta Med Port 2011;24:785- 75. Haffner SM, Mykkänen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000;101:975-80. 76. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. Diabetes Care 2007;30:318-24. 77. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M; the Bruneck study. Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes 2004;53:1782-9. 78. Wu M, Lyons TJ.Treatment approaches for diabetes and dyslipidemia. Horm Res Paediatr. 79. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223. 80. Scheen AJ, Lefebvre PJ. Assessment of insulin resistance in vivo: application to the study of type 2 diabetes. Horm Res 1992;38:19-27. 81. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment. Diabetologia 1985;28:412-9. 82. Han JC, Rutledge MS, Kozlosky M, Salaita CG, Gustafson JK, Keil MF et al. Insulin resistance, hyperinsulinemia, and energy intake in overweight children. J Pediatr 2008; 152:612-7. 83. Cruz ML, Weigensberg MJ, Huang TT, Ball G, Shaibi GQ, Goran MI. The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity. J Clin Endocrinol Metab 2004;89:108-13. 84. Alvarado Soto V, Jiménez Navarrete MF. Síndrome metabólico en pacientes diabéticos tipo 2 e intolerantes a carbohidratos del EBAIS. Acta Méd Costa Rica 2003;45154-7. 85. Aschner P. Metabolic Syndrome as a risk factor for diabetes. Expert Rev Cardiovasc Ther 86. Rosin BL. The progression of cardiovascular risk to cardiovascular disease. Rev Cardiovasc 87. Maiz A. El Síndrome Metabólico y riesgo cardiovascular. Boletín de la Escuela de Medicina. 2005;30:25-30. Disponible en: http://escuela.med.puc.cl/publ/boletin/20051/articulo4.pdf. Fecha de última visita: 31 de Agosto del 2011. 88. Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NECP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-4. 89. Velázquez O, Rosas M, Lara EA, Pastelin HG, Sánchez CC et al., para el Grupo ENSA- 2000. Prevalencia en interrelación de las enfermedades crónicas no transmisibles y factores de riesgo cardiovascular en México. Arch Cardiol Mex 2003;73:62-77. 90. Tousoulis D, Kampoli AM, Papageorgiou N, Androulakis E, Antoniades C, Toutouzas K, Stefanadis C. Pathophysiology of atherosclerosis: the role of inflammation. Curr Pharm Des 2011;17:4089-110. 91. Aso Y, Wakabayashi S, Yamamoto R, Matsutomo R, Takebayashi K, Inukai T. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. Diabetes Care 2005;28:2211-6. 92. Kampoli AM, Tousoulis D, Briasoulis A, Latsios G, Papageorgiou N, Stefanadis C. Potential pathogenic inflammatory mechanisms of endothelial dysfunction induced by type 2 diabetes mellitus. Curr Pharm Des 2011;17:4147-58. 93. Rubio Guerra AF, Durán Salgado MB. Insulin, renin-angiotensin system, aldosterone and endothelial dysfunction. Rev Med Inst Mex Seguro Soc 2011;49:581-4. 94. Donnelly R, Yeung JM, Manning G. Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes. J Hypertens Suppl 2003;21:S7-S12. 95. Naidoo DP. The link between microalbuminuria, endothelial dysfunction and cardiovascular disease in diabetes. Cardiovasc J S Afr 2002;13:194-9. 96. Jensen JS. Microalbuminaria and the risk of atherosclerosis. Clinical epidemiological and physiological investigations. Dan Med Bull 2000;47:63-78. 97. Rowley K, O'Dea K, Best JD. Association of albuminuria and the metabolic syndrome. Curr 98. Frühbeck G. A heliocentric view of leptin. Proc Nutr Soc 2001;60:301-18. 99. Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation 2008;117:3238-49. 100. Phillips LK, Prins JB. The link between abdominal obesity and the metabolic syndrome. 101. Wells JC. Sexual dimorphism of body composition. Best Pract Res Clin Endocrinol 102. Jacobson DL, Knox T, Spiegelman D, Skinner S, Gorbach S, Wanke C. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis 2005; 40:1837-45. 103. Midtvedt K, Hjelmesæth J, Hartmann A, Lund K, Paulsen D, Egeland T, Jenssen T. Insulin resistance after renal transplantation: The effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 2004;15:3233-9. 104. Sheng T, Yang K. Adiponectin and its association with insulin resistance and type 2 diabetes. J Genet Genomics 2008;35:321-6. 105. Fonseca-Alaniz MH, Takada J, Alonso-Vale MIC, Lima FB. O tecido adiposo como centro regulador do metabolismo. Arq Brás Endocrinol Metab 2006;50:216-29. 106. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose 107. Kletzien RF, Clarke SD, Urrich RG. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 1992;41:393-8. 108. Kubota N, Terauchi Y, Kubota T, Kumagai H, Itoh S, Satoh H et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem 2006;281:8748-55. 109. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50;2094-9. 110. Winzell MS, Nogueiras R, Dieguez C, Ahren B. Dual action of adiponectin on insulin secretion in insulin-resistant mice. Biochem Biophys Res Commun 2004;321:154-60. 111. Barbieri M, Bonafè M, Marfella R, Ragno E, Giugliano D, Franceschi C, Paolisso G. LL- paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects. J Clin Endocrinol Metab 2002;87:222-5. 112. He W. PPARgamma2 polymorphism and human health. PPAR Res 2009;2009:849538 113. Barbieri M, Rizzo MR, Papa M, Acampora R, De Angelis L, Olivieri F et al. Role of interaction between variants in the PPARG and interleukin-6 genes on obesity related metabolic risk factors. Exp Gerontol 2005;40:599-604. 114. Vaag A, Poulsen P. Twins in metabolic and diabetes research: what do they tell us? Curr Opin Clin Nutr Metab Care 2007;10:591-6. 115. Poulsen P, Vaag A. The impact of genes and pre- and postnatal environment on the metabolic syndrome. Evidence from twin studies. Panminerva Med 2003;45:109-15. 116. Poulsen P, Vaag A, Kyvik K, Beck-Nielsen H. Genetic versus environmental aetiology of the metabolic syndrome among male and female twins. Diabetologia 2001;44:537-43. 117. Pilote L, Dasgupta K, Guru V, Humphries KH, McGrath J, Norris C et al. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ 2007;176:S1-S44. 118. Rohlfs I, del Mar García M, Gavaldà L, Medrano MJ, Juvinyà D, Baltasar A, Saurina C, Faixedas MT, Muñoz D. Gender and ischemic heart disease. Gac Sanit 2004;18(Suppl 2):55-64. 119. Rubanyi GM, Johns A, Kauser K. Effect of estrogen on endothelial function and angiogenesis. Vascul Pharmacol 2002;38:89-98. 120. Canoy D. Distribution of body fat and risk of coronary heart disease in men and women. 121. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol 122. Polotsky HN, Polotsky AJ. Metabolic implications of menopause. Semin Reprod Med 123. Chae CU, Derby CA. The menopausal transition and cardiovascular risk. Obstet Gynecol 124. Herrera Gómez V, Rodríguez Domínguez L, González O’Farrill S, La O Herrera I, Mas Gómez M, Valdés Almaral O et al. La Gran Crisis Aterosclerótica en mujeres peri-menopáusicas de un área primaria de salud de La Habana. Frecuencia y factores de riesgo. RCAN Rev Cubana Aliment Nutr 2009;19:26-37. 125. Caprio S. Insulin: the other anabolic hormone of puberty. Acta Paediatr Suppl 126. Travers SH, Jeffers BW, Eckel RH. Insulin resistance during puberty and future fat accumulation. J Clin Endocrinol Metab 2002;87:3814-8. 127. Loomba-Albrecht LA, Styne DM. Effect of puberty on body composition. Curr Opin 128. Ruiz JR, Ortega FB, Tresaco B, Wärnberg J, Mesa JL, González Gross M et al.; for the AVENA Study Group. Serum lipids, body mass index and waist circumference during pubertal development in Spanish adolescents: the AVENA Study. Horm Metab Res 2006;38:832-7. 129. Sun SS, Liang R, Huang TT, Daniels SR, Arslanian S, Liu K et al. Childhood obesity predicts adult Metabolic Syndrome: The Fels Longitudinal Study. J Pediatr 2008;152: 191-200. 130. Morrison JA, Friedman LA, Wang P, Glueck CJ et al. Metabolic syndrome in childhood predicts adult Metabolic syndrome and Type 2 Diabetes mellitus 25 to 30 years later. J Pediatr 2008;152:201-6. 131. Amed S, Daneman D, Mahmud FH, Hamilton J. Type 2 Diabetes in children and adolescents. Expert Rev Cardiovasc Ther 2010;8:393-406. 132. Witek J, Witek P, Pańkowska E. Insulin resistance in children. Pediatr Endocrinol 133. Tobisch B, Blatniczky L, Barkai L. Correlation between insulin resistance and puberty in children with increased cardiometabolic risk. Orv Hetil 2011;152:1068-74. 134. Barker DJP. Fetal growth and adult disease. J Obstet Gynaecol 1992;99:275-82. 135. Barker DJP. The fetal origins of diseases of old age. Eur J Clin Nutr 1992;46(Suppl 3): 136. Barker DJP. The fetal origins of coronary heart disease. Acta Paediatr 1997; 137. Hales CN, Barker DJP. The thrifty phenotype hypothesis. Type 2 diabetes. Br Med Bull 138. Roseboom TJ, van der Meulen JHP, Osmond C, Barker DJP, Ravelli ACJ, Schroeder- Tanka JM, van Montfrans GA, Michels RPJ, Bleker OP. Coronary heart disease after prenatal exposure to the Dutch famine, 1944-45. Heart 2000;84:595-8. 139. Stanner SA, Bulmer K, Andrès C, Lantseva OE, Borodina V, Poteen VV, Yudkin JS. Does malnutrition in utero determine diabetes and coronary heart disease in adulthood? Results from the Leningrad siege study, a cross sectional study. BMJ 1997;315:1342-8. 140. Parikh RM, Mohan V. Changing definitions of metabolic syndrome. Indian J Endocrinol 141. WHO World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Geneva: 1999. 142. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR) Diabet Med. 1999;16:442-443. 143. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003;9:237-52. 144. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JL, Donato KA et al. Harmonizing the Metabolic Syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5. 145. Salabarría González JR, Santana Porbén S. Laboratorio Clínico y función renal. Editorial EAE Académica Española. Madrid: 2011. ISBN-13: 978-3846568637. 146. Scarsella C, Después JP. Tratamiento de la obesidad: necesidad de centrar la atención en los pacientes de alto riesgo caracterizados por la obesidad abdominal. Cad Saúde Pública 2003;19:57-9. 147. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation on Obesity. WHO/NUT/NCD/98.1. WHO World Health Organization. Geneva: 1998. 148. Joint WHO/FAO Expert Consultation on Diet, Nutrition and the Prevention of Chronic Diseases. Diet, nutrition and the prevention of chronic diseases: Report of a joint WHO/FAO Expert Consultation. WHO/FAO, Ginebra, 2002. WHO technical report series number 916. Ginebra: 2003. Disponible en: http://whqlibdoc.who.int/trs/WHO_TRS_916.pdf. Consultado por última vez: 21 de Enero del 2011. 149. Lindström J, Eriksson JG, Valle TT, Aunola S, Cepaitis Z, Hakumäki M et al. Prevention of Diabetes Mellitus in Subjects with Impaired Glucose Tolerance in the Finnish Diabetes Prevention Study: Results from a randomized clinical trial. JASN 2003;14(Suppl 2):S108-S113. 150. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K et al., on behalf of the Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. The Lancet 2006;368(9548):1673-9. 151. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S et al., and the Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the Metabolic Syndrome: The Diabetes Prevention Program Randomized Trial. Ann Intern Med 2005;142:611-9. 152. Wang M. Metabolic Syndrome: Underlying mechanisms and drug therapies. John Wiley 153. El-Kaissi S, Sherbeeni S. Pharmacological management of type 2 diabetes mellitus: an update. Curr Diabetes Rev 2011;7:392-405. 154. Kacalska O, Krzyczkowska-Sendrakowska M, Milewicz T, Zabińska-Popiela M, Bereza T, Krzysiek-Maczka G, Krzysiek J. Molecular action of insulin-sensitizing agents. Endokrynol Pol [Poland] 2005;56:308-13. 155. Jermendy G. New clinical data with metformin therapy in patients with diabetes mellitus. 156. Papaetis GS, Orphanidou D, Panagiotou TN. Thiazolidinediones and type 2 diabetes: from cellular targets to cardiovascular benefit. Curr Drug Targets 2011;12:1498-512. 157. Seufert J, Lübben G, Dietrich K, Bates PC. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus. Clin Ther 2004;26:805-18. 158. Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781-90. 159. Krauss RM, Deckelbaum RJ, Ernst N, Fisher E, Howard BV, Knopp RH et al. Dietary guidelines for healthy American adults. A statement for health professionals from the Nutrition Committee, American Heart Association. Circulation 1996;94:1795-1800. 160. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006;114:82-96. 161. Pearson TA, MD, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002;106:388-91. 162. Córdova Villalobos JA, Barriguete Meléndez JA, Lara Esqueda A, Barquera S, Rosas Peralta M, Hernández Ávila M, León May ME, Aguilar Salinas C. Las enfermedades crónicas no transmisibles en México: sinopsis epidemiológica y prevención integral. Salud Pública Méx 2008;5:419-27. 163. Córdova Villalobos JA, Manuell Lee G, Hernández Ávila M, Aguilar Salinas C, Barriguete Meléndez JA, Kuri Morales P, Lara Esqueda A, Álvarez Lucas CA, Molina Cuevas V, Barquera S, Rosas Peralta M, González Chávez A. Plan de prevención clínica de las enfermedades crónicas: sobrepeso, riesgo cardiovascular y diabetes mellitus 2007-2012 y sistema de indicadores de diabetes en México. Diabetes Hoy 2008;9:2144-7. ISSN 1665-8396. 164. Colberg SR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR et al. Exercise and type 2 diabetes: The American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes Care 2010;33:2692-6. 165. Alvarez Gómez J. El Síndrome Metabólico y el entrenamiento físico como pilar importante de su tratamiento. Rev Cubana Cardiol Cir Cardiov 2010;16:51-63. 166. Varady KA, Surabhi B, Church EC, Klempel MC. Short-term modified alternate-day fasting: a novel dietary strategy for weight loss and cardioprotection in obese adults. Am J Clin Nutr 2009;90:1138-43. 167. Ruiz Alvarez V. Ácidos grasos trans. Recomendaciones para reducir su consumo. RCAN 168. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336:1117-24. 169. Willett WC, Sacks F, Trichopoulou A, Drescher G, Ferro-Luzzi A, Helsing E, Trichopoulos D: Mediterranean diet pyramid: a cultural model for healthy eating. Am J Clin Nutr 1995, 61(6 Suppl):1402S-1406S. 170. Tzima N, Pitsavos C, Panagiotakos DB, Skoumas J, Zampelas A, Chrysohoou C, Stefanadis C. Mediterranean diet and insulin sensitivity, lipid profile and blood pressure levels, in overweight and obese people: The Attica study. Lipids in Health and Disease 2007;6:22. Disponible en: http://www.lipidworld.com/content/6/1/22. Fecha de última visita: 8 de Septiembre del 2011. 171. Muzio F, Mondazzi L, Harris WS, Sommariva D, Branchi A. Effects of moderate variations in the macronutrient content of the diet on cardiovascular disease risk factors in obese patients with the metabolic syndrome. Am J Clin Nutr 2007;86:946-51. 172. Muzio F, Mondazzi L, Sommariva D, Branchi A. Long-Term Effects of Low-Calorie Diet on the Metabolic Syndrome in Obese Nondiabetic Patients. Diabetes Care 2005;28:1485-6. 173. Esposito K, Giugliano D. Mediterranean diet and the metabolic syndrome: The end of the beginning. Metab Syndr Related Disorders 2010;8:197-200. 174. Esposito K, Maiorino MI, Di Palo C, Giugliano D. Dietary glycemic index and glycemic load are associated with metabolic control in type 2 diabetes: the Capri experience. Metab Syndr Related Disorders 2010;8:255-61. 175. Salas-Salvadó J, Bulló M, Babio N, Martínez González MA, Ibarrola Jurado N, Basora J, Struch R et al; for the PREDIMED Study investigators. Reduction in the incidence of type 2 diabetes with the Mediterranean Diet: Results of the PREDIMED-Reus Nutrition Intervention Randomized trial. Diabetes Care 2011;34:14-9. 176. Jiménez Gómez Y, Marín C, Pérez Martínez P, Hartwich J, Malczewska-Malec M, Golabek I et al. A low-fat, high-complex carbohydrate diet supplemented with long-chain (n-3) fatty acids alters the postprandial lipoprotein profile in patients with Metabolic Syndrome. J Nutr 2010;140:1595-1601. 177. Azadbakht L, Kimiagar M, Mehrabi Y, Esmaillzadeh A, Padyab M, Hu FB, Willett WC. Soy inclusion in the diet improves features of the metabolic syndrome: a randomized crossover study in postmenopausal women. Am J Clin Nutr 2007;85:735-41. 178. Jebb SA, Lovegrove JA, Griffin BA, Frost GS, Moore CS, Chatfield MD et al; on behalf of the RISCK Study Group. Effect of changing the amount and type of fat and carbohydrate on insulin sensitivity and cardiovascular risk: the RISCK (Reading, Imperial, Surrey, Cambridge, and Kings) trial. Am J Clin Nutr 2010;92:748-58. 179. Gidding SS, Dennison BA, Birch LL, Daniels SR, Gilman MW, Lichtenstein AH et al; for the American Heart Association, American Academy of Pediatrics. Dietary recommendations for children and adolescents: a guide for practitioners: consensus statement from the American Heart Association. Circulation 2005;112:2061-75. 180. Gidding SS, Lichtenstein AH, Faith MS, Karpyn A, Mennella JA, Popkin B et al. Implementing American Heart Association Pediatric and Adult Nutrition Guidelines. Circulation 2009;119:1161-75. 181. Buchwald H, Avidor Y, Braunwald E, Jensen M, Pories W, Fahrbach K et al. Bariatric surgery: a systematic review and metaanalysis. JAMA 2004;292:1724-37. 182. American Diabetes Association: Standards of medical care in diabetes- 2006 (Position Statement). Diabetes Care 2006;29(Suppl 1):S4-S42. 183. Flanebaum L. Mechanisms of weight loss after surgery for clinically severe obesity. Obes 184. Dixon J. Obesity and Diabetes: The impact of bariatric surgery on Type-2 Diabetes. 185. Tsai WS, Inge TH, Burd RS. Bariatric surgery in adolescents: recent national trends in use and in-hospital outcome. Arch Pediatr Adolesc Med. 2007;161:217-21. 186. Fujioka K. Follow-up of nutritional and metabolic problems after bariatric surgery. 187. Magro DO, Geloneze B, Delfini R, Contini Pareja B, Callejas F, Pareja JC. Long-term weight regain after gastric bypass: A 5-year prospective study. Obes Surg 2008;18:648-51. 188. Norma Oficial Mexicana NOM-008-SSA3-2010. Para el tratamiento integral del sobrepeso y la obesidad. Secretaría de Salud. Estados Unidos Mexicanos. Ciudad México: 2010. Disponible en: http://dof.gob.mx/ nota_detalle.php?codigo=5154226&fecha=04/08/2010. Fecha de última visita: 8 de Septiembre del 2011.

Source: http://www.revicubalimentanut.sld.cu/Vol_22_1_Suplemento_2/ReferenciasBibliograficas_SM_Suplemento_2.pdf

2014 step therapy criteria - amerihealth caritas vip plans

Step Therapy Criteria 2014 4 Tier Standard Last Updated: 10/22/2013 ANGIOTENSIN RECEPTOR BLOCKERS Products Affected Criteria Step 1: First line therapy should be losartan or losartan/hctz or valsartan/hctz. Step 2: Second line therapy should be Benicar, Benicar HCT, Edarbi or Edarbyclor. Step 3: Once losartan or losartan/hctz or valsartan/hctz and Benicar, Benicar HCT, Edarbi or Eda

Quarterly progress report

Southeastern Sun Grant Center Quarterly Progress Report Project Title: Biological energy production from biomass by wood-feeding termites Recipient Organization: Mississippi State University Principal Investigator: Dr. Jianzhong Sun, Dr. Yueqing Cao, Dr. Jose Rodriguez Project Location: [Poplarville, MS; Starkville, MS.] Reporting Period: [July 1, 2008 to September 30, 2008]

Copyright © 2010-2014 Internet pdf articles